Literature DB >> 17869518

151st ENMC international workshop: Inflammatory Neuropathy Consortium 13th-15th April 2007, Schiphol, The Netherlands.

M P Lunn1, J M Léger, I S Merkies, P Van den Bergh, I N van Schaik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17869518     DOI： 10.1016/j.nmd.2007.08.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  3 in total

1.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

2.  Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.

Authors:  Ingemar S J Merkies; John-Philip Lawo; Jonathan M Edelman; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Jean-Marc Léger
Journal:  J Peripher Nerv Syst       Date:  2017-06       Impact factor: 3.494

3.  Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Authors:  Jean-Marc Léger; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Amgad Shebl; Artur Bauhofer; Othmar Zenker; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.